Last reviewed · How we verify
NCT06685848
Comparison of Hemanext ONE® System and Conventional Red Blood Cell Transfusion
NA trial testing Hemanext ONE system in Hematologic Neoplasms in 24 participants. Currently enrolling.
15 December 2026
Quick facts
| Lead sponsor | Hemanext |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | crossover |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 24 |
| Start date | 29 November 2024 |
| Primary completion | 15 December 2026 |
| Estimated completion | 15 December 2026 |
| Sites | 1 location across Norway |
Drugs / interventions tested
- Hemanext ONE system
- Conventional RBCs
Conditions studied
- Hematologic Neoplasms — all drugs for Hematologic Neoplasms →
Sponsor
Hemanext
Who can join
18 and older, any sex, with Hematologic Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The overall objective of this study is to collect preliminary effectiveness and safety data on the transfusion of hypoxic RBCs, manufactured with the Hemanext ONE device, in patients with hematological malignancies. The Hemanext ONE device received CE mark in April 2021.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06685848
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hematologic Neoplasms
Currently open trials in the same condition.
- NCT07519811 — LLM-Generated Plain-Language Patient Synopses to Improve Comprehension in Hematology and Oncology (oncOPAL) · NA · recruiting
- NCT07485855 — Influenza Vaccination Strategy for Patients With Hematologic Malignancy · Phase 3 · recruiting
- NCT07162038 — Phase I Trial Integrating HLA-Haploidentical Anti-CD19 CAR-T Cells With Post-Transplantation Cyclophosphamide-Based HLA- · Phase 1 · recruiting
- NCT06433349 — A Multi-center Investigation of Family Health. · recruiting
- NCT06422533 — Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients · NA · recruiting
Other Hemanext trials
Trials by the same sponsor.
- NCT05549232 — Hypoxic Red Blood Cells for Burns and Hematological Malignancies at Haukeland University Hospital · completed
- NCT04418934 — Clinical Investigation to Evaluate the Hemanext® Red Blood Cell Processing System for Extended Storage of Leukoreduced R · Phase 2 · withdrawn
- NCT03301779 — Clinical Investigation to Evaluate the Hemanext® Oxygen Reduction System - Pivotal Trial · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06685848 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Hemanext
- Last refreshed: 7 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06685848.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing